$RGC Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets.
Regencell also entered into a joint venture with Honor Epic Enterprises Limited and is expected to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. https://www.regencellbioscience.com/investor-relations/